Table 1.
Clinical characteristics of SLE patients and healthy controls
| Clinical characteristics | SLE (n=60) | Healthy control (n=30) |
|---|---|---|
| Sex, male/female | 5/60 | 3/30 |
| Age (year) | 32.0 ± 8.10 | 29.0 ± 6.65 |
| Duration (year) | 9.00 ± 4.30 | - |
| SLEDAI scores | 10.6 ± 3.67 | - |
| Disease active, n (%) | 42 (70.0) | - |
| Skin, n (%) | 39 (65.0) | - |
| Kidney, n (%) | 37 (61.7) | - |
| Anti-ds-DNA antibody (IU/ml) | 103.1 ± 20.64 | - |
| CRP (mg/L) | 4.80 ± 1.45 | - |
| ESR (mmH2O) | 31.0 ± 12.8 | - |
| IgG (g/L) | 20.6 ± 4.33 | - |
| IgA (g/L) | 4.81 ± 1.01 | - |
| IgM (g/L) | 1.87 ± 0.46 | - |
| C3 level (g/L) | 0.38 ± 0.07 | - |
| C4 level (g/L) | 0.03 ± 0.01 | - |
| 24 h urine protein (g) | 1.36 ± 0.40 | - |
| Mean prednisone dose, mg/day | 28.1 | - |
| Chloroquine, n (%) | 40 (66.7) | - |
| Immunosuppressantsa, n (%) | 38 (63.3) | - |
a
AZA, LEF, MMF and cyclophosphamide.